Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Financing Activities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash from Financing Activities for 13 consecutive years, with -$400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 7.53% to -$400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.1 million, a 96.36% increase, with the full-year FY2024 number at -$2.5 million, up 98.74% from a year prior.
  • Cash from Financing Activities was -$400000.0 for Q3 2025 at Theravance Biopharma, up from -$503000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $140000.0 in Q2 2022 to a low of -$722.0 million in Q3 2022.
  • A 5-year average of -$63.9 million and a median of -$854000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 3783.98% in 2023, then skyrocketed 96.95% in 2024.
  • Theravance Biopharma's Cash from Financing Activities stood at -$11.3 million in 2021, then tumbled by 214.25% to -$35.5 million in 2022, then crashed by 58.55% to -$56.2 million in 2023, then soared by 99.35% to -$365000.0 in 2024, then decreased by 9.59% to -$400000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Cash from Financing Activities are -$400000.0 (Q3 2025), -$503000.0 (Q2 2025), and -$854000.0 (Q1 2025).